Key result
Antiplatelet agents for atherothrombotic disease are reviewed, summarizing European Society of Cardiology recommendations and real-world data on their use and hemorrhagic risks.
This review summarizes the European Society of Cardiology recommendations and real-world data on the use of antiplatelet agents for atherothrombotic disease.
Answers are grounded in this paper and cite their sources.
Reinforces ESC antiplatelet recommendations; leaves open optimal bleeding-risk mitigation in real-world atherothrombotic disease.
Platelets are components of normal haemostasis, but under certain circumstances, they contribute to coronary occlusion and myocardial ischaemia. Several drugs have been investigated for decades to modulate platelet adhesion and aggregation in coronary artery disease. Although these drugs improve the symptoms and prognosis of millions of patients by reducing arterial thrombosis, they pose a variable risk of haemorrhagic complications. The European Society of Cardiology has published several recommendations on antiplatelet therapy that will be reviewed in this article, together with data from the real-world daily use of these drugs.
No takes yet. Share an insight, caveat, or question.
Sanz‐Ruiz et al. (2008) conducted a review in Atherothrombotic disease. Antiplatelet agents was evaluated. Antiplatelet agents for atherothrombotic disease are reviewed, summarizing European Society of Cardiology recommendations and real-world data on their use and hemorrhagic risks.
Synapse has enriched 10 related papers. Consider them for comparative context: